Haircare, Salon Trends and Hair-Loss Science — 2026-09-14
Dyson has disrupted the styling tool market with the launch of its first-ever dryer brush, the Airsmooth, priced significantly below the Airwrap. Meanwhile, clinical progress in hair-loss treatment continues with new Phase 2/3 data on oral alternatives to minoxidil and international research validating micro-needling techniques for scalp health.
Haircare, Salon Trends and Hair-Loss Science — 2026-09-14
Top developments
Dyson Launches First Dryer Brush, the Airsmooth
On September 8, 2026, during IFA in Berlin, Dyson unveiled ten new products, including its first-ever dryer brush, the Airsmooth, and a new hair straightener, the Corrale CoolShine. The Airsmooth is designed to dry and style simultaneously with heat protection and anti-snag technology, retailing at $249.99—significantly cheaper than the flagship Airwrap. This launch marks a strategic shift to offer a more affordable entry point into Dyson’s high-performance hair care ecosystem, directly competing with mid-tier tools like the Shark FlexStyle.
VDPHL01 Oral Pill Outperforms Minoxidil in Phase 2/3 Trials
A new investigational oral hair loss pill, VDPHL01, has cleared Phase 2/3 trials, demonstrating superior efficacy compared to minoxidil and finasteride in preliminary studies. Dr. Michael Gold, a study investigator, highlighted the drug's potential to offer a more effective and potentially safer alternative for androgenetic alopecia patients who struggle with topical treatments or experience side effects from current oral options. This development represents a significant step forward in the pharmaceutical pipeline for hair restoration.
APR Publishes RF Microneedling Research in International Journal
South Korean beauty tech company APR announced that its joint academic-industry research on high-frequency microneedling (micro-poration) for scalp health improvement has been published in an international academic journal. The study validates the efficacy of APR’s device technology in enhancing scalp conditions and addressing hair loss concerns, reinforcing the trend of integrating medical-grade aesthetic procedures into at-home haircare routines. This publication adds scientific credibility to the growing category of device-assisted topical delivery systems.
P&G Japan Rebrands Pantene Gold Repair with 200% Panthenol
P&G Japan launched a revamped Pantene Gold Repair series on September 7, 2026, featuring a formulation with 200% concentration of panthenol compared to previous iterations. The brand claims this "super-concentrated" formula achieves salon-exclusive repair levels, targeting damaged hair cuticles. This move highlights the ongoing competition in mass-market haircare to deliver "salon-quality" results through over-the-counter products, leveraging high-concentration active ingredients as a key differentiator.
Local view
Japan: French luxury brand Sisley launched its advanced scalp serum, "Hair Ritual Fortifying Serum," in Japan on September 1, 2026. Priced at ¥40,700 for 60ml, the product targets the premium scalp care segment, reflecting the Japanese market's willingness to invest in high-end, skincare-inspired hair treatments.
Korea: Korean media reports a shift in marketing strategies for hair-loss brands, moving away from traditional celebrity endorsements toward "real user" testimonials. Brands are leveraging developers and individuals with personal hair-loss experiences as models, a strategy driven by consumer trust in authentic, experience-based narratives rather than pure celebrity fame.
Context & numbers
- Dyson Airsmooth Price: $249.99, positioning it as a mid-range competitor against the ~$600 Airwrap.
- Sisley Serum Price: ¥40,700 (~$270 USD), indicating strong demand for ultra-premium scalp treatments in Asia.
- Pantene Panthenol Concentration: 200% increase vs. standard formula.
On the radar
- Olaplex Q3 Earnings: Investors and industry analysts are awaiting Olaplex's next quarterly results following their recent turnaround strategy focus on professional channels. Previous quarters showed mixed results with sales dipping 3.8% but beating expectations.
- Exosome Therapy Trials: Multiple exosome and stem cell therapy trials for hair loss are reaching Phase 3 completion in late 2026, which could lead to regulatory approvals or significant data releases in early 2027.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
